Patents Examined by Michail A Belyavskyi
-
Patent number: 11963979Abstract: An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific T cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, for example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy.Type: GrantFiled: June 22, 2018Date of Patent: April 23, 2024Assignees: AlloVir, Inc., Baylor College of Medicine, Wilson Wolf Manufacturing CorporationInventors: Rainer Ludwig Knaus, Katy Rebecca Newton, Juan Vera, Ann Leen, Cliona Rooney, John R. Wilson
-
Patent number: 11959102Abstract: Embodiments of the disclosure include methods and compositions for use of prepared fibroblasts and/or conditioned media therefrom. In particular embodiments, the prepared fibroblasts have enhanced regenerative and may have an increase in secretion of one or more cytokines and/or growth factors; may have an increase in anti-apoptotic activity; and/or may have a modulated immunogenicity. In specific embodiments, the fibroblasts are prepared by exposure to hypoxia and/or carbon monoxide.Type: GrantFiled: December 17, 2018Date of Patent: April 16, 2024Assignee: Figene, LLCInventors: Pete O'Heeron, Thomas Ichim
-
Patent number: 11939596Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.Type: GrantFiled: August 30, 2022Date of Patent: March 26, 2024Assignee: Iovance Biotherapeutics, Inc.Inventors: Seth Wardell, James Bender
-
Patent number: 11931382Abstract: Provided herein are methods and customized media compositions for culturing CIK NKT cells.Type: GrantFiled: July 3, 2022Date of Patent: March 19, 2024Assignee: ImmunityBio, Inc.Inventors: Rohit Duggal, Ranjeet Sinha
-
Patent number: 11913023Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.Type: GrantFiled: September 2, 2021Date of Patent: February 27, 2024Assignee: Walking Fish Therapeutics, Inc.Inventors: Kathleen Boyle, Hangil Park, Srinivas Kothakota, Mark Selby, Thomas Brennan, Lewis T. Williams
-
Patent number: 11905333Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance.Type: GrantFiled: December 22, 2022Date of Patent: February 20, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Irving L. Weissman, Agnieszka Czechowicz, Deepta Bhattacharya, Daniel Kraft
-
Patent number: 11884907Abstract: A culture container for culturing lymphocytes includes an immobilized surface and a non-immobilized surface, wherein the culture container is formed of a gas permeable film, the immobilized surface and the non-immobilized surface are container inner surfaces facing each other, and anti-CD3 antibodies are immobilized in the immobilized surface at a concentration of 10 to 300 ng/cm2.Type: GrantFiled: June 16, 2016Date of Patent: January 30, 2024Assignee: TOYO SEIKAN GROUP HOLDINGS, LTD.Inventors: Takahiko Totani, Satoshi Tanaka, Takeshi Aihara, Yoichi Ishizaki
-
Patent number: 11866688Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.Type: GrantFiled: July 1, 2022Date of Patent: January 9, 2024Assignee: Iovance Biotherapeutics, Inc.Inventors: Cecile Chartier-Courtaud, Krit Ritthipichai
-
Patent number: 11845959Abstract: Transient MLLT3 overexpression in culture may be used to expand human HSCs in vitro, and thereby improve the efficiency and safety of HSC transplantation.Type: GrantFiled: June 16, 2017Date of Patent: December 19, 2023Assignee: The Regents of the University of CaliforniaInventors: Hanna Mikkola, Vincenzo Calvanese, Andrew T. Nguyen
-
Patent number: 11833218Abstract: Described herein are biomimetic Janus particles useful as artificial antigen presenting cells capable of activating T cells in vitro. “Bull's eye” ligand patterns mimicking either the native or reverse organization of the T cell immunological synapse are provided on the surface of nano- or micro-sized particles. Methods for activating T cells in vitro using biomimetic Janus particles described herein are also provided. T cells activated by the biomimetic Janus particles can be used in adoptive immunotherapies for treating cancer, tolerance induction in autoimmune disease, autologous immune enhancement therapy, and viral infection immunotherapy. Also described herein are methods for producing a biomimetic Janus particle.Type: GrantFiled: January 22, 2020Date of Patent: December 5, 2023Assignee: Indiana University Research and Technology CorporationInventor: Yan Yu
-
Patent number: 11802269Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.Type: GrantFiled: October 29, 2019Date of Patent: October 31, 2023Assignee: Poseida Therapeutics, Inc.Inventors: Eric M. Ostertag, Devon Shedlock
-
Patent number: 11773373Abstract: Disclosed is a method for rapidly amplifying CD8+T cells and functional cell subpopulations thereof in vitro. A TLR1/2 agonist, a TLR2/6 agonist and a TLR5 agonist or a combination of above agonists is added to a conventional culture system for in-vitro amplification of CD8+T cells. Recombinant cytokines IL-2, IL-7 and IL-15 as well as magnetic beads coated with an anti-human CD3 antibody and an anti-human CD28 antibody can be further added to the culture system for continuous co-stimulation.Type: GrantFiled: December 15, 2017Date of Patent: October 3, 2023Assignee: Shanghai Innovative Chang'An Biological Technology Co., Ltd.Inventors: Jianqing Xu, Xiaoyan Zhang, Chenli Qiu
-
Patent number: 11739298Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.Type: GrantFiled: November 9, 2021Date of Patent: August 29, 2023Assignee: SDF BioPharma Inc.Inventors: Gerald F. Swiss, David Kiewlich
-
Patent number: 11725187Abstract: It is provided a method of expanding ex vivo hematopoietic stem cells (HSC), the method comprising selecting a population of Endothelial Protein C Receptor (EPCR)+ HSC, culturing the selected HSC thereby expanding said EPCR+ HSC and the use of the expanded EPCR+ HSC for stem cells transplantation.Type: GrantFiled: May 31, 2017Date of Patent: August 15, 2023Assignee: UNIVERSITE DE MONTREALInventors: Guy Sauvageau, Iman Fares, Jalila Chagraoui
-
Patent number: 11702635Abstract: A method to expand hematopoietic stem and progenitor cells (HSPC) wherein the method comprises obtaining an isolated population of HSPC the culturing the isolated population of HSPC in the presence of a histone deacetylase inhibitor (HDAC inhibitor), to form a cultured population, then adding an aminothiol compound to the cultured population.Type: GrantFiled: April 25, 2018Date of Patent: July 18, 2023Assignee: PLASTICELL LIMITEDInventor: Diana Hernandez
-
Patent number: 11673958Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.Type: GrantFiled: March 3, 2014Date of Patent: June 13, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
-
Patent number: 11661598Abstract: A method of screening is provided. In certain embodiments, the method involves a) obtaining the nucleotide sequences of: i. a heavy chain-encoding nucleic acid that encodes the variable domain of a heavy chain of a first antibody of an animal; and ii. a light chain-encoding nucleic acid that encodes the variable domain of a light chain of the first antibody; b) obtaining nucleotide sequences of cDNAs encoding at least a portion of the antibody repertoire of the animal; c) computationally screening the sequences obtained in b) to identify heavy and light chain sequences that are related by lineage to the heavy and light chain sequences of a); and d) testing at least one pair of the heavy and light chain sequences identified in c) to identify a second antibody that binds to the same antigen as the first antibody.Type: GrantFiled: September 25, 2019Date of Patent: May 30, 2023Assignee: EPITOMICS, INC.Inventors: Mark Bushfield, Michael Hadjisavas, Luc Adam
-
Patent number: 11661579Abstract: Methods of culturing cells capable of producing desired proteins to obtain the proteins by use of a medium from which biological components are excluded as much as possible are provided. Specifically, a culture method characterized by culturing while maintaining a specific amino acid in a culture solution at a high concentration, and a cell culture fed-batch medium for use in the method are provided.Type: GrantFiled: March 8, 2019Date of Patent: May 30, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Satoshi Katayama, Shouhei Kishishita, Kunihiko Kodaira, Makoto Sadamitsu, Yoshinori Takagi, Hiroki Matsuda
-
Patent number: 11648293Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: May 16, 2023Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Patent number: 11648278Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.Type: GrantFiled: August 3, 2022Date of Patent: May 16, 2023Assignee: Iovance Biotherapeutics, Inc.Inventors: Seth Wardell, James Bender, Michael T. Lotze